Charles River Laboratories International, Inc. (NYSE:CRL) reported Q2 2017 earnings this Morning, coming in at $1.29 per share, beating Wall Street’s estimates of $1.22 per Share. Revenue for the quarter came in at $469.13 million beating analyst estimates of $458.25 million
Analyst Coverage For Charles River Laboratories International, Inc. (NYSE:CRL)
These are 4 Hold Ratings, 3 Buy Ratings .
The current consensus rating for Charles River Laboratories International, Inc. (NYSE:CRL) is Hold (Score: 2.43) with a consensus target price of $96.93 , a potential (1.46% downside)Recent Insider Trading for Charles River Laboratories International, Inc. (NYSE:CRL)
- On 7/17/2017 George Massaro, Director, sold 3,830 with an average share price of $100.81 per share and the total transaction amounting to $386,102.30.
- On 7/10/2017 James C Foster, Chairman, sold 9,516 with an average share price of $98.92 per share and the total transaction amounting to $941,322.72.
- On 6/22/2017 Davide Molho, Insider, sold 10,948 with an average share price of $100.00 per share and the total transaction amounting to $1,094,800.00.
- On 6/22/2017 James C Foster, Chairman, sold 43,154 with an average share price of $100.00 per share and the total transaction amounting to $4,315,400.00.
- On 6/8/2017 David Ross Smith, Insider, sold 945 with an average share price of $95.00 per share and the total transaction amounting to $89,775.00.
- On 5/26/2017 Davide Molho, Insider, sold 10,976 with an average share price of $92.84 per share and the total transaction amounting to $1,019,011.84.
Recent Trading for Charles River Laboratories International, Inc. (NYSE:CRL) Shares of Charles River Laboratories International, Inc. closed the previous trading session at 97.08 down -1.28 -1.30% with 447,724 shares trading hands.